WAYNE, PA — Palvella Therapeutics, Inc. is set to share important research findings at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference, taking place from October 24-26, 2024, in Phoenix, AZ. The presentations will shed light on their innovative treatment approach for microcystic lymphatic malformations (microcystic LMs) using QTORIN™ rapamycin 3.9% anhydrous gel.
The conference will feature two significant presentations from Palvella Therapeutics. The first presentation is titled “SELVA: A Phase 3 Study with a Fit-For-Purpose Primary Endpoint Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations.” This session will be led by Joyce Teng, M.D., Ph.D., a renowned Professor of Dermatology and Pediatrics at Stanford University. Dr. Teng’s presentation is scheduled for Thursday, October 24, from 4:00 to 5:25 PM MST.
The second presentation, “QTORIN™ rapamycin 3.9% anhydrous gel: A Novel, Dermal-Targeted Topical mTOR inhibitor in Phase 3 for treatment of Microcystic Lymphatic Malformations,” will be delivered by Jeff Martini, Ph.D., Chief Scientific Officer at Palvella Therapeutics. This session will also take place on Thursday, October 24, from 4:00 to 5:25 PM MST.
These presentations will discuss the potential of QTORIN™ rapamycin as a targeted therapy for microcystic LMs and highlight the progress of the Phase 3 SELVA study, which is a 24-week, single-arm, baseline-controlled clinical trial. The study aims to assess the efficacy of QTORIN™ rapamycin for treating this complex condition.
The findings from Palvella’s research are expected to contribute significantly to the field of pediatric dermatology, providing new insights and potential treatment options for those affected by microcystic LMs. Abstracts from the conference will be published in the journal Pediatric Dermatology, ensuring the wide dissemination of these crucial findings.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.